Responses
Clinical and epidemiological research
Extended report
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Compose a Response to This Article
Other responses
No responses have been published for this article.